Drugs / P-321
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02242032 | Jul 2014 → Mar 2015 | dry eye syndrome | Parion Sciences | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02824913 | Jul 2016 → Mar 2017 | dry eye syndrome | Parion Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02831387 | Jul 2016 → Jun 2017 | dry eye syndrome | Parion Sciences | Terminated | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-05-01 | Takeda | Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications takeda.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02831387 ↗ |
| Route | Other | “given two times a day via ocular instillation” NCT02242032 ↗ |